Rovi stock: fundamental analysis
Stocks · ROVI · Healthcare
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. Below are its fundamentals, explained in the order worth reading them: business quality, debt, growth and, last, whether the price is reasonable.
- Price: 57.65 EUR
- Market cap: 2.9B EUR
Data as of September 18, 2026 · Yahoo Finance
Quick read
Business quality
ROE of 28.7%: it earns a high return on shareholders' money. Out of every 100 in sales, 24.0 end up as profit.
Financial health
It holds more cash than debt (net debt/EBITDA of -0.1x): a very comfortable position.
Growth
Revenue is growing 20.0% year on year: a solid pace. Earnings are up 246.7%.
Valuation
It trades at a P/E of 15.9, below the 33.9 median of the healthcare companies we track. A low P/E is not automatically a bargain: it can reflect risks or slower growth.
Dividend
Dividend yield of 1.6% (0.96 EUR per share per year) with a payout ratio of 25.8%.
Tools
All metrics
| Rovi | Sector median | |
|---|---|---|
| Business quality | ||
| ROE | 28.7% | 25.7% |
| ROA | 9.4% | 9.0% |
| Gross margin | 64.7% | 70.5% |
| Operating margin | 9.4% | 28.5% |
| Net margin | 24.0% | 15.6% |
| Financial health | ||
| Net debt/EBITDA | -0.1x | 2.0x |
| Debt/equity | 0.2x | 0.7x |
| Current ratio | 2.1x | 1.3x |
| Growth | ||
| Revenue growth | 20.0% | 10.2% |
| Earnings growth | 246.7% | 139.8% |
| Valuation | ||
| P/E ratio | 15.9x | 33.9x |
| Forward P/E | 17.2x | 16.7x |
| EV/EBITDA | 16.7x | 17.0x |
| Price/book | 4.2x | 4.2x |
| FCF yield | 5.7% | 4.7% |
| Dividend | ||
| Dividend yield | 1.6% | 1.8% |
| Payout ratio | 25.8% | 48.0% |
| Beta (volatility) | 0.2x | 0.3x |
Frequently asked questions
What is Rovi's P/E ratio?
Rovi's P/E is 15.9 based on trailing 12-month earnings and 17.2 on expected earnings. The median for its sector among the companies we track is 33.9. Data as of September 18, 2026.
What dividend does Rovi pay?
Dividend yield of 1.6% (0.96 EUR per share per year) with a payout ratio of 25.8%.
Is Rovi stock expensive?
It trades at a P/E of 15.9, below the 33.9 median of the healthcare companies we track. A low P/E is not automatically a bargain: it can reflect risks or slower growth. This is an educational reading based on ratios, not a buy or sell recommendation.
Does Rovi have a lot of debt?
It holds more cash than debt (net debt/EBITDA of -0.1x): a very comfortable position.
What is Rovi's market cap?
Rovi has a market cap of 2.9B EUR and its shares trade at 57.65 EUR, with a 52-week range of 53.10 EUR to 86.70 EUR (data as of September 18, 2026).
Other companies in the sector
Trailing 12-month metrics. Educational content, not investment advice.